分泌蛋白CRLF1表达对结直肠癌细胞增殖和细胞克隆能力的影响-现代医学

分泌蛋白CRLF1表达对结直肠癌细胞增殖和细胞克隆能力的影响

单位：1. 川北医学院附属医院肝胆外科, 四川南充 637000;
2. 川北医学院肝胆胰肠研究所, 四川南充 637000;
3. 遂宁市中心医院神经中心三病区, 四川遂宁 629000

分类号：R735.34

出版年·卷·期（页码）：2021·49·第九期（995-1001）

摘要：

目的：深入研究细胞因子受体样因子1（CRLF1）表达对结直肠癌细胞增殖和细胞克隆能力的影响。方法：酶联免疫吸附法（ELISA）检测血清中CRLF1表达水平，提取新鲜肿瘤及癌旁组织样本RNA，测定CRLF1的相对表达量。培养人结直肠癌细胞株HCT116和SW620，合成si-NC和si-CRLF1小干扰RNA，对HCT116和SW620细胞进行转染，使用实时聚合酶链反应（real-time PCR）及ELISA法验证转染效率，CCK8实验检测转染后结直肠癌细胞增殖能力的变化，克隆形成实验检测细胞克隆形成的能力，流式细胞术检测细胞凋亡水平。Western blot检测AKT信号通路及变化。结果：结直肠癌患者血清CRLF1水平显著高于健康捐献者血清。结直肠癌组织中CRLF1 mRNAG表达水平显著高于癌旁组织。分别在两种细胞系中通过转染si-CRLF1以实现敲低CRLF1表达。敲低CRLF1表达后结直肠癌细胞HCT116和SW620的细胞增殖能力及细胞克隆形成能力明显减弱（P<0.05），细胞凋亡率显著升高。敲低CRLF1表达后p-AKT表达水平显著降低。结论：CRLF1表达通过调控AKT信号通路调控结直肠癌进展，该蛋白可能成为诊断结直肠癌的生物标志物以及治疗结直肠癌的潜在靶点。

Objective: To investigate the effect of cytokine receptor like factor l(CRLF1) expression on the proliferation and clonal ability in colorectal cancer cells. Methods: Enzyme linked immunosorbent assay (ELISA) was used to detect the CRLF1 level in serum of colorectal cancer patients and healthy donors. RNA was extracted from fresh cancer tissues and tissues adjacent to cancer, the relative mRNA expression of CRLF1 was determined. Human colorectal cancer cell lines HCT116 and SW620 were cultured. si-NC and si-CRLF1 siRNA were synthesized and transfected into HCT116 and SW620 cells. After verifying the transfection efficiency by real-time PCR and ELISA, CCK8 assay was performed to detect the proliferation ability of colorectal cancer cells. Clone formation assay was also used to detect the ability of clone formation, flow cytometry was used to detect the apoptosis status in colorectal cancer cells after transfection. AKT signaling pathway activity was detected by Western blot. Results: The serum CRLF1 level in colorectal cancer patients was significantly higher than that in healthy donors. Consistently, the expression level of CRLF1 mRNAin colorectal cancer tissue was significantly higher than that in tissue adjacent to cancer. In HCT116 and SW620 cell lines, the expression of CRLF1 was significantly downregulated by si-CRLF1, which significantly reducing the proliferation and colon formation (P<0.05), and inducing apoptosis in both cell lines. In addition, downregulation of CRLF1 significantly reduced the expression of p-AKT. Conclusion: CRLF1 expression regulates the progression of colorectal cancer cells though AKT signaling pathway. CRLF1 may become a biomarker for the diagnosis and a potential target for colorectal cancer.

参考文献：

[1] MILLER K D, NOGUEIRA L, MARIOTTO A B, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5):363-385.
[2] HAGGAR F A, BOUSHEY R P.Colorectal cancer epidemiology:incidence, mortality, survival, and risk factors[J]. Clin Colon Rect Surg, 2009, 22(4):191-197.
[3] WENG M, WU D, YANG C, et al. Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer[J]. Transl Res, 2017, 181:108-120.
[4] 王希君, 沈容芳, 王想, 等.甲胎蛋白高表达和低表达肝细胞肝癌的基因表达谱差异分析[J]. 中华肿瘤杂志, 2020, 42(5):396-402.
[5] 安澜, 曾红梅, 郑荣寿, 等.2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10):721-727.
[6] GELFMAN S, WANG Q, MCSWEENEY K M, et al. Annotating pathogenic non-coding variants in genic regions[J]. Nat Commun, 2017, 8(1):236.
[7] YU S T, ZHONG Q, CHEN R H, et al. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways[J]. Cell Death Dis, 2018, 9(3):371.
[8] TORMO A J, MELIANI Y, BEAUPRÉ L A, et al. The composite cytokine p28/cytokine-like factor 1 sustains B cell proliferation and promotes plasma cell differentiation[J]. J Immunol, 2013, 191(4):1657-1665.
[9] DAGONEAU N, BELLAIS S, BLANCHET P, et al. Mutations in cytokine receptor-like factor 1(CRLF1) account for both Crisponi and cold-induced sweating syndromes[J]. Am J Hum Genet, 2007, 80(5):966-970.
[10] Kass D J, YU G, LOH K S, et al. Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4⁺ T cells in murine lungs:evidence for an antifibrotic role in bleomycin injury[J]. Am J Pathol, 2012, 180(5):1963-1978.
[11] HUARTE M, GUTTMAN M, FELDSER D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response[J]. Cell, 2010, 142(3):409-419.
[12] BASAK D, UDDIN M N, HANCOCK J.The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC)[J]. Cancers (Basel), 2020, 12(11):3336.
[13] KOVEITYPOUR Z, PANAHI F, VAKILIAN M, et al. Signaling pathways involved in colorectal cancer progression[J]. Cell Biosci, 2019, 9:97.
[14] LI Q, DAI Y, WANG F, et al. Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer[J]. Neoplasma, 2016, 63(6):977-983.
[15] PAN S, LIU Y, LIU Q, et al. HOTAIR/miR-326/FUT6 axis facilitates colorectal cancer progression through regulating fucosylation of CD44 via PI3K/AKT/mTOR pathway[J]. BBA-Mol Cell Res, 2019, 1866(5):750-760.
[16] SOLEIMANI A, RAHMANI F, FERNS G A, et al. Role of Regulatory oncogenic or tumor suppressor miRNAs of PI3K/AKT signaling axis in the pathogenesis of colorectal cancer[J]. Curr Pharm Design, 2018, 24(39):4605-4610.
[17] BAHRAMI A, KHAZAEI M, HASANZADEH M, et al. Therapeutic potential of targeting PI3K/AKT pathway in treatment of colorectal cancer:rational and progress[J]. J Cell Biochem, 2018, 119(3):2460-2469.
[18] SONG M, BODE A M, DONG Z, et al. AKT as a therapeutic target for cancer[J]. Cancer Res, 2019, 79(6):1019-1031.
[19] POLIVKA J J, JANKU F.Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Therapeut, 2014, 142(2):164-175.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录